Loading...

ZYDUSLIFE Zydus Lifesciences Ltd Litigation, disputes or regulatory action Announcement

Zyds

ZYDS

Zydus Lifesciences Ltd

(ZYDUSLIFE)

2024 Announcement

Show Summary

Summary

Positive Trial Results

Management Change

ESG Rating Update

Share Certificate Loss

Earnings Call Transcript

USFDA Inspection Update

USFDA Inspection Closure

Financial Results Published

Investor Conference

Management Change

Director Re-appointment

Investor Call Recording

Q1 Earnings Report

Investor Presentation

NOC Approval Notice

Earnings Call Details

Acquisition Completed

Acquisition Update

Share Certificate Loss

Annual Meeting Notice

FDA Approval Update

New Subsidiary USA

Compliance Report

Share Certificate Loss

Annual General Meeting

Share Certificate Loss

Shareholder Notice

Acquisition Update

Investor Presentation

Share Certificate Notice

FDA Inspection Closure

Management Change

FDA Inspection Report

FDA Inspection Success

ESG Rating Assigned

Acquisition of Shares

Licensing Agreement

Biologics Acquisition

Share Acquisition

Investor Conference

Fast Track Designation

Share Certificate Loss

Earnings Call Transcript

FDA Approval Received

Financial Results Published

Investor Call Recording

Authority Change

Annual Compliance Report

Financial Results

Investor Presentation

Management Change

Director Re-appointed

Loss of Share Certificates

Earnings Call Details

Management Change

USFDA Inspection Closure

Stake Acquisition

Acquisition Update

Strategic Partnership

Patent Litigation Update

Tender Offer Announcement

Investment in Feldan

Patent Litigation Update

New Subsidiary France

Dematerialization Compliance

Acquisition Update

Share Certificate Loss

FDA Approval Received

USFDA Inspection Closure

Lost Share Certificates

Investment in Illexcor

Acquisition Plans

Investor Conference

Major Acquisition

Share Certificate Loss

Revised ESG Score

FDA Approval Received

Launch of ANVIMO

Combination Vaccine Develop...

GST Demand Notice

Investor Conference

USFDA Inspection Closure

New Product Agreement

USFDA Inspection Closure

Partnership Announcement

Investor Conference

Earnings Call Transcript

Management Changes

Financial Results Published

ESG Rating Update

Investor Call Update

Financial Results Q3

Q3 Earnings Presentation

25 Years Celebration

Share Certificate Loss

Earnings Call Notice

Padma Bhushan Award

GST Demand Notice

USFDA Designation Granted

GST Demand Notice

Compliance Confirmation

Loss of Share Certificates

Zydus-CVS Agreement

FDA Drug Review

ESG Rating Update

Management Change

Credit Rating Update

Acquisition Update

Equity Disinvestment

Equity Disinvestment

GST Demand Notice

Lost Share Certificate

Earnings Call Transcript

Financial Results Update

Investor Call Update

Financial Results Q2 FY25

Investor Presentation

Q2 FY25 Earnings Call

Nesher Merger Approval

WHO Prequalifies Vaccine

FDA Approval Received

New Clinical Trials

Dematerialization Compliance

FDA Approval Awarded

Share Certificate Loss

Tax Credit Dispute

FDA Approval Received

New Drug Development

Investor Conference

Business Acquisition

Investor Plant Visit

Exclusive Licensing Agreement

Lost Share Certificate

Clinical Trial Success

Tax Demand Order

USFDA Warning Letter

Tax Demand Notice

Tax Demand Notice

Tax Credit Order

USFDA Warning Letter

Tax Demand Order

Equity Stake Acquisition

Regulatory Action

Investor Conference

Tax Demand Order

FDA Approval Received

Investor Presentation

Stake Acquisition

Zydus Acquires Sterling

Investor Conference

Tax Credit Order

Tax Demand Order

Earnings Call Transcript

Tax Demand Order

Financial Results Publication

Director Change

Investor Call Outcome

Financial Results Announcement

Investor Presentation

USFDA Approval for Valbenaz...

Tax Credit Issue

Share Certificate Loss Notice

Product Approval in Mexico

Receipt of Penalty Order

Financial Results Announcement

USFDA Approval for Valsarta...

Zydus Lifesciences Approval...

Newspaper Notice Publication

FDA Inspection Completion

FDA Inspection Update

Newspaper Publication

Patent Licensing Agreement

AGM Notification

Regulatory Action

Approval Received

Equity Shares Dematerializa...

Newspaper Publication

Rectification Order

Newspaper Publication

Investor Meeting

Medication Approval

Acquisition Announcement

Completion of Clinical Trial

Earnings Call Transcript

Financial Results Publication

Investor Call Outcome

Compliance Submission

Financial Results Announcement

investor presentation

Appointment of Director

Exclusive Licensing Agreement

Newspaper Publication

Zydus Lifesciences Trial Co...

Approval from USFDA for Dap...

Stake Sale Update

Zokinvy Acquisition

Rights Acquisition

Announcement of Disinvestment

Correction Disclosure

Correction Disclosure

Tax Demand Order

Tax Demand Order

Tax Demand Notice

Received Demand Order-In-Or...

Tax Demand Notice

Newspaper Publication

USFDA Approval for Tretinoi...

Regulatory Action

USFDA Inspection

Drug Application in China

Zydus product launch announ...

Therapeutics Approval

Certificate Submission

Equity Shares Cancellation ...

Compliance Certificate

Disclosure of Equity Shares

Disclosure of Share Sale

Equity Shares Sale

Equity Sale Disclosure

FDA Inspection Update

Disclosure Under PIT Regula...

Equity Shares Sale

Equity Share Sale

Insider Trading Disclosure

Equity Buyback Correction

Extinguishment of Shares

Insider Trading Disclosures

Buyback Announcement

FDA Approval for Chlorproma...

Tax Demand Order

FDA Inspection Outcome

Investor Meeting

Buyback of Shares

Buyback Offer Letter

WHO Prequalification Approval

Incorporation in UAE

Earnings Call Transcript

Investor Conference

Buyback Announcement

Board Resolution-Buyback

Board Resolution Buyback

Publication of Financial Re...

Update on Buyback

Financial Results and Buyba...

Investor Presentation

Investor Conference

Demand Notice - CGST Jabalpur

Approval for Gabapentin Tab...

Licensing Agreement

Certificate Confirmation

Newspaper Advertisement

Notice of Demand

Tax Demand Order

Assessment Order on Input T...

GST Demand Order

Assessment Order

Regulatory Action

GST Demand Order

Tax Demand Notice

Inspection observations

Newspaper Publication

Dissolution Of Wholly Owned...

Phase II clinical trial of ...

GST Demand Notice

Email ID Change

Licensing Agreement

GST Demand Order

Approval for Ivabradine Tab...

Transcript Release

Newspaper Publication

Licensing Agreement

Publication of Financial Re...

Investor Conferences

Financial Performance

Investor Presentation

Acquisition Completed

Licensing Agreement

Joint Promotion Agreement

Acquisition Agreement Execu...

Acquisition of LiqMeds Group

Licensing Agreement

Newspaper Publication

Clinical Trial Initiation

FDA approval for ZITUVIOTM

Newspaper Publication

Certificate under Reg. 74 (...

US FDA Approval

Newspaper Publication

Phase 1 Clinical Trials

Investor Conference

Product Approval

EIR Report Received

Acquisition of equity stake

Investor Presentation

Investor Conference

Incorporation of Wholly Own...

Investor Conference

Newspaper Publication

Approval from USFDA

Equity, Debt, VC, Private E...

Equity acquisition

Financial Statements

Financial Statements

Investor Meetings

Asset Acquisitions

Schedule Change

Increase in Dividend Rate

Financial Statements

Equity, Debt, VC, Private E...

Operational Disruption

Secondary Offerings

Merger of Equals

Financial Statements

Financial Statements

Post-Market Surveillance

US FDA Inspection

US FDA Inspection

Investor Meetings

Product Launches

Asset Acquisitions

Injectables Manufacturing

New Product Launches

Product Approvals

New Product Launches

Voluntary Delisting

Participation in Conference

Manufacturing Facility Insp...

Earnings Guidance

Financial Statements Public...

Audio recording availability

Financial Statements Disclo...

Financial Statements

Earnings Report

Financial Statements

Regulatory Compliance

New Product Launches

External Links:

Data:

Zydus Lifesciences Ltd received a tax demand order for Rs. 167.60 million due to alleged ineligible input tax credits from FY 2017-18 to 2019-20, which the company plans to challenge, noting no material impact on its operations.

AI Assistant

Zydus Lifesciences Ltd

2024

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.